UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/031,509	05/21/2002	Eric Paul Krenning	0702-020040 6829	
	7590 01/10/2007 AW FIRM, P.C.	EXAMINER		
700 KOPPERS 436 SEVENTH	BUILDING	HUI, SAN MING R		
PITTSBURGH			ART UNIT	PAPER NUMBER
			1617	
				<u> </u>
			MAIL DATE	DELIVERY MODE
			01/10/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	_	
10/031,509	KRENNING ET AL.		
Examiner	Art Unit	_	
San-ming Hui	1617		

	San-ming Hui	1617	
The MAILING DATE of this communication appe	ars on the cover sheet with the	correspondence add	ress
THE REPLY FILED <u>28 September 2006</u> FAILS TO PLACE THI	S APPLICATION IN CONDITION	FOR ALLOWANCE.	
1.  The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliant time periods:	the same day as filing a Notice of ving replies: (1) an amendment, af tice of Appeal (with appeal fee) in	Appeal. To avoid aba fidavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)
a) The period for reply expires 5 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I Examiner Note: If box 1 is checked, check either box (a) or TWO MONTHS OF THE FINAL REJECTION. See MPEP 7	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailin (b). ONLY CHECK BOX (b) WHEN TH	ng date of the final rejecti	ion.
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	on which the petition under 37 CFR 1. tension and the corresponding amount shortened statutory period for reply origr than three months after the mailing described in the mail of the mail	of the fee. The appropr ginally set in the final Offi	iate extension fee ce action; or (2) as
<ol> <li>The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exte a Notice of Appeal has been filed, any reply must be filed</li> </ol>	nsion thereof (37 CFR 41.37(e)), t	o avoid dismissal of th	
AMENDMENTS		*	
<ol> <li>The proposed amendment(s) filed after a final rejection,</li> <li>They raise new issues that would require further co</li> <li>They raise the issue of new matter (see NOTE below)</li> </ol>	nsideration and/or search (see NC		ecause
(c) They are not deemed to place the application in be appeal; and/or	tter form for appeal by materially re	educing or simplifying	the issues for
(d) They present additional claims without canceling a	-	jected claims.	
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1	* **		·
<ol> <li>The amendments are not in compliance with 37 CFR 1.1</li> <li>Applicant's reply has overcome the following rejection(s)</li> </ol>		ompliant Amendment	(PTOL-324).
<ol> <li>Applicant's reply has overcome the following rejection(s)</li> <li>Newly proposed or amended claim(s) would be a non-allowable claim(s).</li> </ol>		, timely filed amendme	ent canceling the
7.  For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows:		ill be entered and an e	explanation of
Claim(s) allowed: Claim(s) objected to:			
Claim(s) rejected: <u>53,55-58 and 60-63</u> . Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
<ol> <li>The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e).</li> </ol>			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appe	eal and/or appellant fai	ils to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after of	entry is below or attact	ned.
11. ☑ The request for reconsideration has been considered bu See Continuation Sheet.	t does NOT place the application	in condition for allowa	nce because:
12. ☐ Note the attached Information Disclosure Statement(s). 13. ☐ Other:	(PTO/SB/08) Paper No(s)		
		San-ming Hui Primary Examiner	4-7
		Art Unit: 1617	

## **Continuation Sheet (PTO-303)**

**Application No. 10/031,509** 

Continuation of 3. NOTE: the newly added claims changes the scope of the claims and therefore raises new issue and requires new consideration by the Examiner.

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's arguments filed September 28, 2006 averring the cited prior arts' failure to teach the same amount of amino acids per dose have been considered, but are not found persuasive, as discussed in the previous office action, the dose of the amino acids taught in the cited prior arts are very similar to what is recited herein. Therefore, optimization of the therapeutic parameters such as dosage of the actives would be considered obvious as being within the purview of one of skilled in the art, absent evidence to the criticality of dosage recited.

Applicant's arguments filed September 28, 2006 averring the cited prior arts teaching multiple amino acids being used have been considered, but are not found persuasive. Although Hammond teaches other amnio acids to be administered, the essential active ingredients, as taught by the cited prior arts as a whole, are lysine, or polylysine, and arginine. The cited prior arts as a whole provide motivation to one of ordinary skill in the art to employ essentially lysine or polylysine with argnine. Furthermore, the dosage of the amino acids employed is taught in the cited prior arts. Therefore, possessing the teachings of the cited prior arts, one of ordinary skill in the art would have employed the herein claimed amino acids in a method of inhibiting renal uptake of proteins and peptides.

No unanswered arguments are seen to be present herein.